Browse the evidence

The doubly labeled water method provides accurate assessment of human energy expenditure under free living conditions.

Practitioners can use the doubly labeled water method for accurate energy expenditure assessments in free living individuals.

Calculations from oxygen consumption and carbon dioxide production can provide erroneous results when several biochemical pathways are engaged.

Practitioners should be cautious when interpreting energy expenditure calculations, especially when multiple metabolic pathways are involved.

Obesity accompanies an increasing burden of metabolic disease among people living with HIV (PWH).

Healthcare providers should be aware of the increased risk of metabolic diseases in PWH with obesity.

Contemporary antiretroviral therapy (ART) regimens, particularly integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF), are contributors to weight gain and obesity in PWH.

Clinicians should consider the impact of specific ART regimens on weight management in PWH.

Metabolic dysregulation is linked to ectopic fat deposition and alterations in immune cell populations in adipose tissue among PWH.

Understanding these links can help in developing targeted interventions for obesity in PWH.

There is a lack of evidence on the efficacy of various methodologies used by physique competitors to improve body composition.

Practitioners should be cautious about methodologies lacking evidence.

Semaglutide may improve wait-list times for renal transplantation by overcoming obesity as a barrier.

Addressing obesity in patients may facilitate their eligibility for renal transplantation.

There was a decline in resting metabolic rate (RMR) out of proportion to the decrease in body mass, with substantial metabolic adaptation.

Practitioners should be aware of the potential for metabolic adaptation when designing weight loss programs.

Despite relative preservation of FFM, marked slowing of resting metabolism out of proportion to weight loss is not avoided by the addition of an exercise program.

Practitioners should consider that exercise alone may not prevent metabolic slowing during weight loss.

Gender, household size, and education were associated with GLP-1 use and interest.

Marketers should consider demographic factors when targeting potential GLP-1 consumers.

The therapeutic efficacy of poly-agonists is likely to change the treatment paradigm for obesity.

Healthcare providers may need to adapt to new treatment protocols involving poly-agonists.

The use of medications for obesity will likely require lifelong treatment.

Practitioners should prepare for long-term management strategies when prescribing obesity medications.

Persistence in the OMM-eligible cohort was 73.8%.

High persistence rates suggest good adherence to tirzepatide among eligible patients.

Real-world evidence suggests slower tirzepatide dose escalation than in clinical trials.

Practitioners may need to adjust expectations regarding dose escalation in real-world settings.

Bariatric surgery reduces TRL apoB-100 concentration due to reduced production and increased clearance.

Clinicians should consider the impact of bariatric surgery on VLDL particle levels in patient management.

Bariatric surgery reduces TRL apoB-48 concentration due to reduced production.

Healthcare providers should note the reduction in chylomicron levels post-surgery for better patient outcomes.

NAFLD should be understood as part of a systemic disease characterized by abnormal fat accumulation in tissues other than adipose tissue.

Understanding NAFLD as a systemic disease can improve patient management strategies.

DTC genetic tests are marketed with faux scientific authority, potentially confusing consumers.

Practitioners should help consumers navigate the complexities of DTC genetic test marketing.

Obesity is projected to affect approximately half the US population by the year 2035.

Practitioners should be aware of the increasing prevalence of obesity for public health planning.

Designer drugs using mono, dual, and triple agonists of GLP-1, GIP, and glucagon can promote weight loss without effort.

Practitioners may consider these drugs as potential options for patients struggling with obesity.

There are fundamental biological principles that raise questions about the therapies for obesity.

Practitioners should be aware of the complexities and potential limitations of obesity therapies.

The question of ideal macronutrient composition for metabolic syndrome is difficult to address and control in clinical practice.

Recognize the complexities involved in dietary recommendations for metabolic syndrome.

Muscle tissue protein synthesis and breakdown rates range between 1% and 2% across the day in vivo in humans.

Understanding the turnover rates can help in designing effective training and nutrition strategies.

Testosterone replacement therapy significantly improved insulin resistance as measured by HOMA-IR from 4.6 ± 1.7 to 0.5 ± 0.2 (P < 0.001).

Testosterone replacement therapy may be effective in improving insulin sensitivity in hypogonadal patients.